BFM
CNSP icon

Boothbay Fund Management’s CNS Pharmaceuticals CNSP Stock Holding History

Boothbay Fund Management’s Portfolio CNSP Stock Details CNSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64.6K Hold
13,524
– – ﹤0.01% 2079
2026
Q1 		$32.3K Hold
13,524
– – ﹤0.01% 1945
2025
Q4 		$71K Buy
+13,524
New +$101K ﹤0.01% 1787

Other funds holding CNSP

IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
SCM
Stonepine Capital Management Bend, Oregon $177M AUM 91.13% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
BC
Barrett & Company Providence, Rhode Island $357M AUM 22.45% 1-Year Est. Return
DB
Danske Bank Copenhagen K, Denmark $50.6B AUM 42.84% 1-Year Est. Return

Boothbay Fund Management's CNSP Position: Q2 2026 in Review

Boothbay Fund Management held its CNS Pharmaceuticals (CNSP) position steady in Q2 2026 at 13,524 shares worth $64.6K. The position accounts for ﹤0.01% of the portfolio, ranked #2079.

Boothbay Fund Management first reported a position in CNSP in Q4 2025 and has held it in 3 quarters since. The position peaked at $71K in Q4 2025. 11 funds tracked by Wall St. Rank hold CNSP as of Q2 2026.

  • Boothbay Fund Management held 13,524 shares of CNS Pharmaceuticals worth $64.6K as of Q2 2026.
  • Boothbay Fund Management left its CNS Pharmaceuticals share count unchanged in Q2 2026.
  • CNS Pharmaceuticals made up ﹤0.01% of Boothbay Fund Management's portfolio in Q2 2026, its #2079 holding.
  • Boothbay Fund Management first reported a position in CNS Pharmaceuticals in Q4 2025 and has held it in 3 quarters since.
  • Boothbay Fund Management's CNS Pharmaceuticals position peaked at $71K in Q4 2025.
  • 11 funds tracked by Wall St. Rank held CNS Pharmaceuticals as of Q2 2026.

Based on Boothbay Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.